Vesicle Therapeutics Inc.
The University of Colorado Connection
Vesicle Therapeutics is a Longmont-based biotechnology company developing programmable extracellular vesicles, known as “gectosomes,” to deliver macromolecular therapeutics to intracellular targets. Founded by Xuedong Liu (CU Boulder Biochemistry), the company builds upon research from his lab focused on engineering vesicles for targeted delivery. Gectosomes are designed to encapsulate therapeutic proteins and nucleic acids, facilitating their delivery into cells and enabling applications such as genome editing and treatment of diseases like cancer and neurodegeneration. Vesicle Therapeutics has received National Institutes of Health (NIH) SBIR and STTR funding to advance its platform, including projects targeting familial hypercholesterolemia and neurodegenerative diseases.
Funding Status and Investment Opportunities
- Industry Applications: Biotech, Therapeutics
- Funding Stage: Seed Round
- Contact for Investment Inquiries: Curtis Woodard , curtis.woodard@vesicletherapeutics.com
Technology Development Funding
U.S. National Institutes of Health (NIH)
This page was last updated on March 12, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.